| Literature DB >> 32062445 |
L Jeung1, L M G Smits2, E L J Hoogervorst3, B W van Oosten4, S T F M Frequin3.
Abstract
A 38-year-old man with relapsing remitting multiple sclerosis (RRMS) developed a tumefactive demyelinating lesion (TDL) after being clinically and radiologically stable on fingolimod for the last five years. TDLs in MS tend to occur early on in the disease and are uncommon in longstanding MS. Compared to other immune modifying drugs used in MS, there is a relatively high and still increasing number of reports describing the development of TDL under treatment with fingolimod, suggesting a causal relation.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32062445 DOI： 10.1016/j.msard.2020.101978
Source DB: PubMed Journal: Mult Scler Relat Disord ISSN： 2211-0348 Impact factor: 4.339